Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) establishes evidence-based guidelines for utilizing pharmacogenetic information for certain priority drugs. Warfarin, clopidogrel and simvastatin are cardiovascular drugs that carry strong prescribing guidance by CPIC. The respective pharmacogenes for each of these drugs exhibit considerable variability amongst different ethnic/ancestral/racial populations. Race and ethnicity are commonly employed as surrogate biomarkers in clinical practice and can be found in many prescribing guidelines. This is controversial due to the large variability that exists amongst different racial/ethnic groups, lack of detailed ethnic information and the broad geographic categorization of racial groups. Using a retrospective analysis of electronic health records (EHR), we sought to determine the degree to which self-reported race/ethnicity contributed to the probability of adverse drug reactions for these drugs. All models used individuals self-reporting as White as the comparison group. The majority of apparent associations between different racial groups and drug toxicity observed in the “race only” model failed to remain significant when we corrected for covariates. We did observe self-identified Asian race as a significant predictor (p = 0.016) for warfarin hemorrhagic events in all models. In addition, patients identifying as either Black/African-American (p = 0.001) or Other/Multiple race (p = 0.019) had a lower probability of reporting an adverse reaction than White individuals while on simvastatin even after correcting for other covariates. In both instances where race/ethnicity was predictive of drug toxicity (i.e., warfarin, simvastatin), the findings are consistent with the known global variability in the pharmacogenes described in the CPIC guidelines for these medications. These results confirm that the reliability of using self-identified race/ethnic information extracted from EHRs as a predictor of adverse drug reactions is likely limited to situations where the genes influencing drug toxicity display large, distinct ethnogeographic variability.

Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis

“…Although these findings suggest that patients with DM should avoid using ACEIs, clinical decision-making should be based on weighing the advantages and disadvantages in realworld settings for specific patients. Many drug clinical trials may have assumed that different ethnicities treated with drugs would have varying types or degrees of side effects [47,48]. While mechanisms explaining this phenomenon remain unclear, the findings of this meta-analysis indicated that, compared with patients from America and Europe, there was a significant correlation between the use of ACEIs and the risk of lung cancer in patients from Asia (Supplementary Fig.…”

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

“…For example, certain anti-hypertensive medications are less effective in Blacks compared to Whites [ 27 ]. In addition, racial variation in adverse effects has been well demonstrated [ 28 , 29 ]. Notably, adverse reactions to anti-convulsive medications vary considerably between Whites and Asians with Vietnamese ancestry [ 30 ], emphasizing the need to investigate drug efficacy in minorities.…”

The Apportionment of Pharmacogenomic Variation: Race, Ethnicity, and Adverse Drug Reactions

“…Given what is known about the apportionment of human genetic variation, the majority of pharmacogenomic variation is expected to fall within rather than between racial and ethnic groups. If this proves to be the case, then race and ethnicity are expected to hold low predictive value for the genetic risk of ADRs 18 . In other words, according to the logic of Lewontin and his intellectual heirs, race and ethnicity are poor proxies for genetic diversity and thus irrelevant for pharmacogenomic informed therapeutic decision making.…”